Mirum Pharmaceuticals (MIRM) files Form 144: proposed resale of vested RSUs

Rhea-AI Filing Summary

Mirum Pharmaceuticals submitted a Form 144 notice reporting proposed sales of Common Stock tied to Restricted Stock Units vesting under a registered plan. The filing lists a broker Morgan Stanley Smith Barney LLC and shows recent dispositions by a holder, including multiple small share sales in January–February 2026.

Insights

Securities Compliance Analyst

Form 144 discloses proposed resale of vested compensation shares via a broker.

The notice lists Common Stock tied to Restricted Stock Units vesting under registered plan and identifies Morgan Stanley Smith Barney LLC as the broker. The filing documents recent past sales by a holder in 01/22/2026, 01/26/2026, and 02/02/2026.

Cash‑flow treatment or aggregate offering totals beyond per‑sale entries are not stated in the excerpt; subsequent filings would show actual execution details and proceeds reporting.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	4732	438372.48	60341617	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/15/2026	Restricted Stock Units vesting under registered plan	Issuer			4732	03/15/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jolanda Howe c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	926	86419.16
Jolanda Howe c/o Mirum Pharmaceuticals, Inc. 989 E. Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/26/2026	842	80993.67
Jolanda Howe c/o Mirum Pharmaceuticals, Inc. 989 East Hillsdale Boulevard, Suite 300 Foster City CA 94404	Common Stock	02/02/2026	968	99997.79

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mirum Pharmaceuticals' Form 144 (MIRM) report?

It reports proposed sales of Common Stock tied to vested Restricted Stock Units under a registered plan. The filing names a broker and lists recent small dispositions dated 01/22/2026, 01/26/2026, and 02/02/2026.

Who is the broker listed on the Form 144 for MIRM?

The broker is Morgan Stanley Smith Barney LLC, with an address at 1 New York Plaza. The filing associates the broker with proposed resale activity of Common Stock.

Does the Form 144 show shares sold already by an insider?

Yes; the filing records past sales of Common Stock by a holder in the three months prior to the notice. Examples include sales of 926, 842, and 968 shares on listed dates.

Are the proposed offering totals or proceeds disclosed in this excerpt?

The excerpt does not provide an aggregate offering total or proceeds amount. It lists individual sale entries and identifies the security type as Common Stock tied to RSU vesting.

Which holder's recent sales are shown as examples in the filing?

The filing shows multiple entries for Jolanda Howe with sales of 926, 842, and 968 Common Stock shares on dates in January and February 2026.